Published in Ann Oncol on October 29, 2011
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol (2012) 0.90
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) (2013) 0.87
Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma (2015) 0.86
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. J Clin Oncol (2016) 0.84
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res (2014) 0.80
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. Ann Oncol (2015) 0.79
Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma? J Comput Assist Tomogr (2016) 0.78
A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Arch (2012) 0.78
Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas. Biomark Cancer (2014) 0.77
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget (2016) 0.77
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther (2016) 0.76
Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells. Mol Med Rep (2016) 0.75
Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. Front Oncol (2016) 0.75
Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med (2016) 0.75
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J Hematol Oncol (2017) 0.75
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol (2014) 0.75
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open (2016) 0.75
Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget (2016) 0.75
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas. Oncotarget (2017) 0.75
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep (2017) 0.75
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med (2001) 16.65
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res (2001) 5.40
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med (1998) 4.18
Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell (1998) 3.71
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A (1997) 3.22
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 3.08
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol (2000) 2.99
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol (2001) 2.68
MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. Radiology (2001) 2.54
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer (2009) 2.52
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer (1999) 2.49
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol (2013) 2.41
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res (2001) 2.29
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.24
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol (2005) 2.24
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol (2000) 2.22
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer (2003) 2.20
Insecticidal activity of recent bacterial isolates and their toxins against mosquito larvae. Nature (1973) 2.17
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol (2004) 2.08
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 2.06
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Pathogenesis of Bacillus sphaericus strain SSII-1 infections in Culex pipiens quinquefasciatus (equal to C. pipiens fatigans) larvae. J Invertebr Pathol (1975) 1.94
Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut (1999) 1.91
Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer (2001) 1.86
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer (2006) 1.85
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol (2001) 1.83
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol (2004) 1.80
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer (2000) 1.78
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78
Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg (1999) 1.76
Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg (2001) 1.73
Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol (2001) 1.72
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer (2001) 1.71
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Health-related quality of life among children and adolescents: associations with obesity. Int J Obes (Lond) (2006) 1.67
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol (2010) 1.65
Delayed treatment of traumatic rupture of the thoracic aorta with endoluminal covered stent. Circulation (1999) 1.65
Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol (2000) 1.64
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol (2005) 1.59
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol (1991) 1.56
Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int J Cancer (1996) 1.54
The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol (2012) 1.53
Bioassay of three strains of Bacillus sphaericus on field-collected mosquito larvae. J Invertebr Pathol (1977) 1.50
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 1.48
Prostaglandins and anti-inflammatory drugs in the dog knee joint. J Pharm Pharmacol (1972) 1.47
Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med (1990) 1.46
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol (2007) 1.45
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol (2010) 1.45
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol (2004) 1.42
Extraskeletal osteosarcoma: analysis of outcome of a rare neoplasm. Sarcoma (2000) 1.42
A review of PARP inhibitors: from bench to bedside. Ann Oncol (2010) 1.41
Bacillus sphaericus Neide as a pathogen of mosquitoes. J Invertebr Pathol (1965) 1.40
Spindle cell rhabdomyosarcoma (so-called) in adults: report of two cases with emphasis on differential diagnosis. Am J Surg Pathol (1998) 1.39
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Randomized trial of Cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis (2007) 1.37
Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol (2004) 1.37
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol (2012) 1.35
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer (2010) 1.33
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol (2007) 1.33
Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment. Arch Surg (2001) 1.29
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol (1999) 1.29
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27